Literature DB >> 32527198

B55α/PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling: A Complementary Approach To Disrupt Pathological Vessels?

Manuel Ehling1,2, Ward Celus1,2, Rosa Martín-Pérez1,2, Roser Alba-Rovira1,2,3, Sander Willox1,2, Donatella Ponti1,2,4, Maria C Cid3, Elizabeth A V Jones5, Giusy Di Conza1,2, Massimiliano Mazzone1,2.   

Abstract

RATIONALE: How endothelial cells (ECs) migrate and form an immature vascular plexus has been extensively studied. Yet, mechanisms underlying vascular remodeling remain poorly established. A better understanding of these processes may lead to the design of novel therapeutic strategies complementary to current angiogenesis inhibitors.
OBJECTIVE: Starting from our previous observations that PP2A (protein phosphatase 2) regulates the HIF (hypoxia-inducible factor)/PHD-2 (prolyl hydroxylase 2)-constituted oxygen machinery, we hypothesized that this axis could play an important role during blood vessel formation, tissue perfusion, and oxygen restoration. METHODS AND
RESULTS: We show that the PP2A regulatory subunit B55α is at the crossroad between vessel pruning and vessel maturation. Blood vessels with high B55α counter cell stress conditions and thrive for stabilization and maturation. When B55α is inhibited, ECs cannot cope with cell stress and undergo apoptosis, leading to massive pruning of nascent blood vessels. Mechanistically, we found that the B55α/PP2A complex restrains PHD-2 activity, promoting EC survival in a HIF-dependent manner, and furthermore dephosphorylates p38, altogether protecting ECs against cell stress occurring, for example, during the onset of blood flow. In tumors, EC-specific B55α deficiency induces pruning of immature-like tumor blood vessels resulting in delayed tumor growth and metastasis, without affecting nonpathological vessels. Consistently, systemic administration of a pan-PP2A inhibitor disrupts vascular network formation and tumor progression in vivo without additional effects on B55α-deficient vessels.
CONCLUSIONS: Our data underline a unique role of the B55α/PP2A phosphatase complex in vessel remodeling and suggest the use of PP2A-inhibitors as potent antiangiogenic drugs targeting specifically nascent blood vessels with a mode-of-action complementary to VEGF-R (vascular endothelial growth factor receptor)-targeted therapies. Graphical Abstract: A graphical abstract is available for this article.

Entities:  

Keywords:  apoptosis; blood vessels; developmental biology; endothelial cells; oncology; perfusion; vascular endothelial growth factor

Mesh:

Substances:

Year:  2020        PMID: 32527198     DOI: 10.1161/CIRCRESAHA.119.316071

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  10 in total

1.  Allosteric activation of PP2A inhibits experimental abdominal aortic aneurysm.

Authors:  Xianming Zhou; Chao Zhang; Fei Xie; Wei Wei; Rui Li; Qian Xu; Yu Wang; Philip A Klenotic; Goutham Narla; Nianguo Dong; Zhiyong Lin
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

2.  A cannabidiol aminoquinone derivative activates the PP2A/B55α/HIF pathway and shows protective effects in a murine model of traumatic brain injury.

Authors:  Carmen Navarrete; Adela García-Martín; Alejandro Correa-Sáez; María E Prados; Francisco Fernández; Rafael Pineda; Massimiliano Mazzone; Marina Álvarez-Benito; Marco A Calzado; Eduardo Muñoz
Journal:  J Neuroinflammation       Date:  2022-07-09       Impact factor: 9.587

3.  Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy: Is Inhibition of the PP2A/B55α Complex the Answer?

Authors:  John D Martin; Dan G Duda; Rakesh K Jain
Journal:  Circ Res       Date:  2020-08-27       Impact factor: 17.367

Review 4.  Apoptosis in resistance arteries induced by hydrogen peroxide: greater resilience of endothelium versus smooth muscle.

Authors:  Rebecca L Shaw; Charles E Norton; Steven S Segal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-02-19       Impact factor: 4.733

5.  Protein Phosphatase 2A Mediates YAP Activation in Endothelial Cells Upon VEGF Stimulation and Matrix Stiffness.

Authors:  Xiao Jiang; Jiandong Hu; Ziru Wu; Sarah Trusso Cafarello; Mario Di Matteo; Ying Shen; Xue Dong; Heike Adler; Massimiliano Mazzone; Carmen Ruiz de Almodovar; Xiaohong Wang
Journal:  Front Cell Dev Biol       Date:  2021-05-13

6.  Neuropilin 1 and its inhibitory ligand mini-tryptophanyl-tRNA synthetase inversely regulate VE-cadherin turnover and vascular permeability.

Authors:  Noemi Gioelli; Lisa J Neilson; Na Wei; Giulia Villari; Wenqian Chen; Bernhard Kuhle; Manuel Ehling; Federica Maione; Sander Willox; Serena Brundu; Daniele Avanzato; Grigorios Koulouras; Massimiliano Mazzone; Enrico Giraudo; Xiang-Lei Yang; Donatella Valdembri; Sara Zanivan; Guido Serini
Journal:  Nat Commun       Date:  2022-07-20       Impact factor: 17.694

Review 7.  Molecular mechanisms of endothelial dysfunction in Kawasaki-disease-associated vasculitis.

Authors:  Yu Qiu; Yulin Zhang; Yifei Li; Yimin Hua; Yue Zhang
Journal:  Front Cardiovasc Med       Date:  2022-08-08

8.  Biphasic Effect of Pirfenidone on Angiogenesis.

Authors:  Donghao Gan; Wenxiang Cheng; Liqing Ke; Antonia RuJia Sun; Qingyun Jia; Jianhai Chen; Zhanwang Xu; Juan Xu; Peng Zhang
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

9.  Protein Phosphatase 2A Deficiency in Macrophages Increases Foam Cell Formation and Accelerates Atherosclerotic Lesion Development.

Authors:  Rui Li; Chao Zhang; Fei Xie; Xianming Zhou; Xingjian Hu; Jiawei Shi; Xinling Du; Zhiyong Lin; Nianguo Dong
Journal:  Front Cardiovasc Med       Date:  2022-01-18

10.  Betulinic Acid Hydroxamate is Neuroprotective and Induces Protein Phosphatase 2A-Dependent HIF-1α Stabilization and Post-transcriptional Dephosphorylation of Prolyl Hydrolase 2.

Authors:  María E Prados; Alejandro Correa-Sáez; Juan D Unciti-Broceta; Martín Garrido-Rodríguez; Carla Jimenez-Jimenez; Massimiliano Mazzone; Alberto Minassi; Giovanni Appendino; Marco A Calzado; Eduardo Muñoz
Journal:  Neurotherapeutics       Date:  2021-08-02       Impact factor: 7.620

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.